Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

According to the Global Burden of Disease Study BMI Collaborators analysis published in ... should hold on buying more NVO stock, as it appears that Eli Lilly’s research expenses are to pay ...

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Eli Lilly? Access our full analysis report here ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

To make the world smarter, happier, and richer. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches ...

According to the Global Burden of Disease Study BMI Collaborators analysis published in The Lancet this ... investors should hold on buying more NVO stock, as it appears that Eli Lilly’s research ...

Trump's order looking to cut prescription drug prices is bearish for drug stocks at the surface, but is the worst already priced in?

Amid concerns over trade restrictions and a weakening economy, some investors are seeking stability in dividend-paying stocks ...

Despite Lars Fruergaard Jørgensen's resignation as Novo Nordisk's CEO, its stock price has risen 10% over the past two weeks.

The world’s largest pharmaceutical stock, Eli Lilly and Company LLY ... the dominant player in the weight-loss drug market. This analysis will look at the most important details surrounding ...